Montara Therapeutics, a San Francisco, CA-based biotech company empowering brain-selective therapies for CNS diseases, raised $20M in Seed funding.
Backers included SV Health Investors’ Dementia Discovery Fund, Two Bear Capital, Dolby Family Ventures, and KdT Ventures, along with new investments from BEVC and additional investors, bringing the total amount to $28M. In connection with the financing, Troy E. Wilson, Ph.D., J.D., has joined Montara as an Independent Director and Chairman of the Board. Dr. Wilson, a serial entrepreneur and current President and CEO of Kura Oncology, has founded and operated multiple companies, including Kura, Avidity Biosciences, Wellspring Biosciences, Araxes Pharma, Intellikine, and Ambrx. Dr. Wilson is also participating in the Seed round as an investor.
The company intends to sue the funds to expand operations and its R&D efforts.
Led by Nicholas T. Hertz, Ph.D., Founder and CEO, Montara is a preclinical-stage biopharmaceutical company pursuing novel approaches to develop safer and more efficacious treatments for neurological diseases. Its BrainOnly™ platform is designed to improve the therapeutic index of CNS drugs and enable higher, more effective dosing of CNS-targeted therapies by blocking peripheral side effects, addressing major safety and tolerability challenges in the treatment of various neurological diseases.
FinSMEs
13/03/2025